In-vitro dissolution testing of 5-aminosalicylic acid release from pH dependent mesalazine formulations
نویسندگان
چکیده
منابع مشابه
In-vitro dissolution testing of 5-aminosalicylic acid release from pH dependent mesalazine formulations.
Figure 2 Experiment B: dissolution of Salofalk 1.5 g granules (batch no. 10F18833L) and Mezavant 1200 mg (batch no VB032) at sequential pH 1.0, 6.0, and 6.8 (n=6). We have read with interest the abstract presented at the last ECCO Congress by Tenjarla & Abinusawa1. While we agree with the authors' final statement that ‘consideration of the potential release profiles [of 5-ASA] may be a useful t...
متن کاملRelease of 5-Aminosalicylic Acid (5-ASA) from Mesalamine Formulations at Various pH Levels
INTRODUCTION Oral formulations of 5-aminosalicylic acid (5-ASA) for treatment of ulcerative colitis have been developed to minimize absorption prior to the drug reaching the colon. In this study, we investigate the release of 5-ASA from available oral mesalamine formulations in physiologically relevant pH conditions. METHODS Release of 5-ASA from 6 mesalamine formulations (APRISO®, Salix Phar...
متن کاملMesalazine (5-aminosalicylic acid) induced chronic hepatitis.
BACKGROUND Treatment of ulcerative colitis or Crohn's disease with sulphasalazine causes several adverse effects, including hepatitis. Sulphasalazine is cleaved by colonic bacteria into 5-aminosalicylic acid and sulphapyridine. Received wisdom was that 5-aminosalicylic acid was topically active, whereas sulphapyridine was absorbed and caused immunoallergic side effects. Mesalazine, a slow relea...
متن کاملGastrointestinal release behaviour of modified-release drug products: dynamic dissolution testing of mesalazine formulations.
The aminosalicylate mesalazine (mesalamine) forms the mainstay of treatment in ulcerative colitis (UC), a disease for which many commercial modified-release products have been developed with the aim of providing targeted gastrointestinal release. The release profiles of five of these commercial formulations were evaluated in bicarbonate buffer using a novel dissolution model that mimics the dyn...
متن کاملWhat dose of 5-aminosalicylic acid (mesalazine) in ulcerative colitis?
Sulphasalazine was developed in the 1930s, initially for use in patients with rheumatic polyarthritis. However, its modest eVects in arthritis were soon overshadowed by the striking benefits seen when the drug was given to patients with active colitis. Controlled clinical trials confirmed the early favourable impressions and established a role for sulphasalazine in the treatment of active disea...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Journal of Crohn's and Colitis
سال: 2011
ISSN: 1873-9946
DOI: 10.1016/j.crohns.2011.04.003